Quarterly Statement Of Cash Flows

OncoTherapy Science, Inc. - Filing #7253509

Concept 2024-04-01 to
2025-03-31
As at
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
Quarterly statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-813,992,000 JPY
-813,125,000 JPY
-1,285,713,000 JPY
-1,006,572,000 JPY
Impairment losses
279,000 JPY
154,564,000 JPY
Interest expenses
1,201,000 JPY
218,000 JPY
Decrease (increase) in trade receivables
-63,233,000 JPY
87,484,000 JPY
Decrease (increase) in inventories
-4,870,000 JPY
25,618,000 JPY
Other, net
-20,500,000 JPY
-16,233,000 JPY
Subtotal
-811,284,000 JPY
-1,225,319,000 JPY
Interest paid
-1,311,000 JPY
-109,000 JPY
Income taxes paid
-2,425,000 JPY
-2,561,000 JPY
Net cash provided by (used in) operating activities
-815,021,000 JPY
-1,227,990,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-279,000 JPY
-2,627,000 JPY
Net cash provided by (used in) investing activities
-279,000 JPY
-33,354,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
1,174,772,000 JPY
682,552,000 JPY
Other, net
-1,000 JPY
-2,000 JPY
Net cash provided by (used in) financing activities
1,121,527,000 JPY
671,365,000 JPY
Net increase (decrease) in cash and cash equivalents
306,227,000 JPY
-589,978,000 JPY
Cash and cash equivalents
833,883,000 JPY
527,656,000 JPY
1,117,635,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.